Duke Clinical Research Institute

Business news, market intelligence, and global industry analysis.

The Latest

Representative image of financial growth metrics and capital allocation themes linked to Westaim Corporation’s Q4 2025 results, as investors assess Ceres Life Insurance Company’s annuity expansion and Arena Investors Group Holdings’ turnaround outlook.

Westaim (TSXV: WED) posts wider FY2025 loss as Ceres Life ramp and Arena reset reshape 2026 outlook

4DMedical (ASX: 4DX) secures CE Mark for CT:VQ and raises A$83m to accelerate European commercial launch

Representative image of premium spirits bottles and market screens illustrating the Pernod Ricard SA and Brown-Forman Corporation merger talks that could reshape the global spirits industry.

Pernod Ricard and Brown-Forman confirm merger talks that could reshape the global spirits industry

Judge blocks Pentagon from blacklisting Anthropic: ‘Classic First Amendment retaliation’

Alnylam Pharmaceuticals (NASDAQ: ALNY) to launch global Phase 3 trial of RNAi therapy zilebesiran in high-risk hypertension patients

Alnylam Pharmaceuticals (NASDAQ: ALNY) moves its RNAi drug zilebesiran into a global Phase 3 trial for hypertension after ESC 2025 data showed sustained blood pressure reductions.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

August 30, 2025